XtalPi Stock

xtalpi.comHealthcare / BioTech & PharmaFounded: 2016

XtalPi is a pharmaceutical technology company focused on reinventing the industry's approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform.

Register for Details

For more details on financing and valuation for XtalPi, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for XtalPi.

Register Today

Other companies like XtalPi in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$4.74B

News Highlights

XtalPi to collaborate with Eli Lilly on using AI and robotics in drug discovery · TechNode
Pharmaceutical technology company XtalPi has announced a collaboration with US drug maker Eli Lilly. The partnership will focus on using AI and robotics in drug discovery, with an upfront payment of up to $250 million. XtalPi will use its ID4Inno™ small-molecule drug discovery platform, combining AI, autonomous labs, and expert domain knowledge for efficient drug discovery processes.
XtalPi announces $250m AI drug discovery collaboration with Eli Lilly
XtalPi has entered into a $250m partnership with Eli Lilly to utilise artificial intelligence (AI) for drug discovery. The collaboration will leverage XtalPi’s integrated AI capabilities and robotics platform to design and deliver drug candidates. The AI drug discovery solution will be used to create a novel compound, which will be advanced by Lilly through clinical and commercial development.
Chinese pharma firm uses AI to find new industrial materials
XtalPi, a pharmaceutical firm backed by Tencent and Softbank, plans to leverage AI to expand into materials science and discover new industrial materials. The company also intends to significantly expand its facilities in Shanghai and Hong Kong, but has no immediate plans for an IPO.
Updated on: Oct 1, 2023